| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000019274 |
| Receipt No. | R000022287 |
| Scientific Title | The analysis of drug-related anaphylactic cases by using PMDA database |
| Date of disclosure of the study information | 2015/10/08 |
| Last modified on | 2022/10/17 (Ver. 7) |
| Basic information | ||
| Public title | The analysis of drug-related anaphylactic cases by using PMDA database | |
| Acronym | Analysis of anaphylactic cases from PMDA database
(PMDA-An analysis) |
|
| Scientific Title | The analysis of drug-related anaphylactic cases by using PMDA database | |
| Scientific Title:Acronym | Analysis of anaphylactic cases from PMDA database
(PMDA-An analysis) |
|
| Region |
|
|
| Condition | ||
| Condition | Anaphylaxis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To clarify mainstay drugs and drugs with high mortality rate in drug-related anaphylaxis cases |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To clarify an outline of drug related anaphylaxis cases in Japan |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Cases that were suspected as adverse reaction of drugs and reported to PMDA | |||
| Key exclusion criteria | None | |||
| Target sample size | 15000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Hospital Organization Sagamihara National Hospital | ||||||
| Division name | Department of Allergy, Clinical Research Center for Allergy and Rheumatology | ||||||
| Zip code | |||||||
| Address | 18-1, Sakuradai, Minami-ku, Sagamihara, Kanagawa, Japan, 252-0392 | ||||||
| TEL | 042-742-8311 | ||||||
| mebisawa@foodallergy.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Hospital Organization Sagamihara National Hospital | ||||||
| Division name | Department of Allergy, Clinical Research Center for Allergy and Rheumatology | ||||||
| Zip code | |||||||
| Address | 18-1, Sakuradai, Minami-ku, Sagamihara, Kanagawa, Japan, 252-0392 | ||||||
| TEL | 042-742-8311 | ||||||
| Homepage URL | |||||||
| sugizaki@foodallergy.jp | |||||||
| Sponsor | |
| Institute | National Hospital Organization Sagamihara National Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Society of Allergology |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立病院機構相模原病院(神奈川県)Sagamihara National Hosital |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | |||||||
| Number of participants that the trial has enrolled | 16916 | ||||||
| Results | |||||||
| Results date posted | |||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | |||||||
| Participant flow | |||||||
| Adverse events | |||||||
| Outcome measures | |||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Study design: retrospective cohort study
Subjects: Cases that were suspected as adverse reaction of drugs and reported to PMDA from April 2004 to February 2018 Analyzing items: Number of cases of each year, therapeutic category, product, route of administration etc. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022287 |